JPM: Pharma Must Change Tone Deaf Message On Pricing
This article was originally published in Scrip
Executive Summary
When biopharma executives were asked during the 34th Annual J.P. Morgan Healthcare Conference what they thought of public concerns about prescription drug pricing, some dismissed it as a political issue and others offered the same old explanations about recovering the cost of developing innovative medicines, yet the industry appears dismayed about the ongoing uproar.
You may also be interested in...
Industry Tightens Drug Pricing Message, But Loose Ends Remain
Drug makers are under increasing pressure regarding the cost of their medicines, but instead of pointing fingers at payers for patients' out-of-pocket costs, the industry has shifted to a more collaborative tone, although some tensions will take time to overcome.
BIO 2016 Notebook: Pricing And Innovation Hot Topics In San Francisco
Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.